Sonablate® Brought to Texas by One of the Early Advocates for HIFU Prostate Ablation

Share Article

Dr. James Cochran brings Sonablate to the Midwest, performing his first U.S.-based prostate HIFU procedure in Dallas, Texas

Sonablate trans-rectal HIFU probe
“We are exceedingly proud to be able to provide this minimally invasive prostate procedure to men who have been seeking an alternative option in prostate care..." - Dr. James Cochran

SonaCare Medical, LLC announces that Sonablate HIFU prostate ablation is now available in Dallas, Texas. Dr. James Cochran recently launched his U.S. HIFU program, performing his inaugural procedure at Texas Health Presbyterian Hospital in Dallas on March 16th, 2016.

Prior to Sonablate’s FDA clearance, Dr. James Cochran had been performing HIFU procedures at locations outside of the United States since 2005. He has been an avid supporter of HIFU for over a decade and holds a longstanding relationship with SonaCare Medical, serving as a clinical investigator for a SonaCare Medical U.S. clinical trial investigating the use of HIFU for Benign Prostatic Hyperplasia (BPH) in 1999.

“My team and I are excited to be the first to offer Sonablate HIFU in Texas and the surrounding states,” comments Dr. James Cochran. “We are exceedingly proud to be able to provide this minimally invasive prostate procedure to men who have been seeking an alternative option in prostate care. I am eager to witness the acceptance of HIFU ablation technology throughout the United States, and look forward to the additional advancements it inspires across an evolving medical landscape.”

SonaCare Medical's Chief Executive Officer, Dr. Mark Carol, comments “Dr. Cochran has been one of the most committed long term supporters of focused ultrasound ablation in the U.S., treating patients at multiple locations outside the U.S. over the past 10+ years. I am personally delighted that James now has the opportunity to bring his experience with Sonablate to Dallas, Texas, where I am sure he will continue to further the development of prostate ablation using Sonablate as a robust clinical tool.”

Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit


SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com

Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erica Griffith
Follow >
Visit website